Cognoa Licenses Innovative Digital Therapeutic Technology

April 10, 2019 GMT

PALO ALTO, Calif., April 10, 2019 (GLOBE NEWSWIRE) -- Cognoa, a company at the forefront of digital behavioral health for children, today announces it has exclusively licensed technology from the Stanford University School of Medicine to accelerate development and worldwide commercialization of a novel digital therapeutic for children with autism spectrum disorder (ASD). Underscoring the need for earlier access to personalized therapies, Cognoa has already received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its first digital therapeutic device using the technology.


Cognoa’s ASD digital therapeutic uses the licensed technology to target the core deficit of social-emotional reciprocity in autism. Social-emotional reciprocity is the ability to recognize, interpret and respond to social cues such as facial expressions and emotional states. Study results from a randomized clinical trial, recently published by peer-reviewed medical journal, JAMA Pediatrics, showed children who used the technology on Google Glass tested better for socialization, play and coping skills than those who only received standard of care behavioral therapy for ASD. Cognoa is actively working to further develop and productize the technology for increased accessibility on more broadly available digital platforms.

“Digital therapeutics can extend a therapist’s reach into the home, complementing in-person therapies for improved life-long outcomes,” said Brent Vaughan, CEO and co-founder of Cognoa, Inc. “We know that many families are facing obstacles to get their children the help they need. This technology accelerates our goal to empower parents with access to evidence-based solutions so they can more directly impact the progress of their children.”


Today, most children in the U.S. who receive an autism diagnosis, and subsequent treatments, do so after the age when interventions have the greatest opportunity to impact the life of the child. Cognoa will integrate the licensed technology into its precision health platform for the earlier diagnosis and treatment of pediatric behavioral health conditions. By uniquely combining artificial intelligence machine learning diagnostics and therapeutics within the same platform, Cognoa is working to create a new standard in behavioral healthcare so that children receive an earlier diagnosis and more effective therapies for the greatest potential impact on their lives.

About Cognoa, Inc.Cognoa is developing AI-based digital diagnostics and personalized therapies that are designed to make earlier diagnoses and effective treatments available to more children to improve outcomes and lower behavioral healthcare costs. When more physicians are empowered to identify behavioral conditions and developmental delays earlier, more children can benefit from treatments at a younger age when there is the greatest potential for improved lifelong outcomes. Cognoa currently provides the Cognoa Child Development app via partnerships with employers, payers and ABA therapy centers to empower parents and caregivers to better support their children’s unique behavioral health and growth. Cognoa intends to seek FDA review and clearance that will allow the company to support its diagnostic and therapeutic claims with robust clinical data. For more information, visit

Media Contact Courtney Calderon Uproar PR for Cognoa 321-236-0102 ext. 234